Coave Therapeutics
French tech company | Builders Republic
About
Clinical-stage gene therapy biotech developing treatments for rare inherited eye and central nervous system diseases — built on a proprietary delivery platform that improves how therapies reach and penetrate target cells, with programs addressing Parkinson's, Gaucher disease and the inherited retinal disorder Stargardt.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2014
- City
- PARIS
- Region
- IDF
- Legal name
- COAVE THERAPEUTICS (COAVE THERAPEUTICS)
- SIREN
- 800830721
- Tracked rounds
- 2
- Amount raised
- 65 M€ raised since 2020
Funding rounds
- Series A — 2025
- Series B — 2021
Investors
- bpifrance
- Bpifrance Life Sciences Venture
- Eurazeo
- eureKARE
- Fund+
- GO Capital
- Invus
- Kurma Partners
- Novo Holdings
- Omnes Capital
- Pontifax
- Relyens Innovation Santé
- Seroba Life Sciences
- Seroba.
- Théa Open Innovation
- Turenne Capital
- UI Investissement
- V-Bio Ventures